Research programme: TLR9 agonists - Coley/sanofi-aventis

Drug Profile

Research programme: TLR9 agonists - Coley/sanofi-aventis

Alternative Names: AVE 7279; CpG 7279; TLR Therapeutics - Coley/sanofi-aventis

Latest Information Update: 13 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Coley Pharmaceutical Group
  • Class Oligonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Allergic rhinitis; Asthma

Most Recent Events

  • 16 Nov 2007 A lead compound from this programme has entered clinical trials, preclinical development with other compounds is ongoing
  • 16 Sep 2004 Preclinical trials in Allergic rhinitis (inhalation)
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthélabo to form sanofi-aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top